A phase I/II study of the PARP inhibitor, ABT-888 plus 5-fluorouracil and oxaliplatin (modified FOLFOX-6) in patients with metastatic pancreatic cancer.
Michael J. Pishvaian(The University of Texas MD Anderson Cancer Center), Jonathan R. Brody(Oregon Health & Science University), Sandeep Apte, Amy Hankin(National Institutes of Health), Aiwu Ruth He(Georgetown University), Louis M. Weiner(Georgetown University), Susan J. Littman(Thomas Jefferson University), Jimmy J. Hwang(University of California, San Francisco), J. Marshall(Fox Chase Cancer Center), Agnes Witkiewicz, Rebecca Slack
Cited by 6
Related Papers
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
|Clinical Cancer Research|2009|1.4k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
Monoclonal Antibodies in Cancer Therapy
|Antibodies|2020|799